Wednesday, 18th November International Celiac Disease Symposium 2026

Invited Speakers:

• Professor Daniel Agardh, Lund University - 'New Prospective Insights from TEDDY'
• Dr Marisa Stahl, Children's Hospital Colorado - 'Lessons from the ASK Study'

Followed by Panel Discussion.

Abstract Speakers:

• PFAS in early life and risk of celiac disease: Results from two Scandinavian cohorts - Ketil Stordal
• INTERIM RESULTS FROM TWO ONGOING PRIMARY PREVENTION TRIALS IN CHILDREN AT GENETIC RISK OF CELIAC DISEASE: THE PRECISE AND GRAIN STUDIES - Carin Andrén Aronsson
• Functional characterization of the celiac disease risk gene PUS10 identifies a novel regulator of epithelial inflammatory programming - Ainara Castellanos-Rubio

Invited Speakers:

• Professor Chris Goodnow, Garvan Institute of Medical Research - 'CD19 B cell Depletion in Celiac Disease and Other Autoimmune Diseases'
• Professor Ranjeny Thomas, University of Queensland - 'Rheumatoid Arthritis: Translational Lessons for Celiac Disease'

Abstract Speakers:

• A Duodenal Pre Gluten-Challenge Interferon-γ/Antigen-Presentation State Predicts Susceptibility to Gluten-Induced Mucosal Injury in Celiac Disease - Aline Pesi
• Using cryo-electron tomography and volume electron microscopy methods to localize active transglutaminase 2 and define the ultrastructure of dendritic cells and the small intestine - Krystal Brodsky
• Less than half of patients newly positive for tissue transglutaminase antibodies undergo upper endoscopy for diagnostic confirmation: A population-based study from Alberta, Canada - James A King
• JAK inhibition suppresses interferon driven epithelial stress pathways in celiac disease - Veera Räkköläinen
• Serum proteomic profiling of celiac disease: Extending inflammatory signatures with the novel Protein XI multiplex platform - Jostein H. Ibsen
• Global Preparedness of Celiac disease from the lens of dietitians: Are we ready for the future? - Suyasha Gupta
• Tryptophan restores AhR signaling in celiac disease: A double-blinded randomized placebo-controlled exploratory study. - Utkarshini Kirtikar
• Nationwide survey of coeliac disease serology testing in Italy - Francesca Manza
• Is prenatal exposure to per- and polyfluoroalkyl substances (PFAS) a risk factor for celiac disease? - Christina Elise Holm-Larsen

• EVQ-001, a NanoDisc Antigen-Specific Immune Tolerance Therapy for Celiac Disease - Weston L Daniel
• In Vivo Evaluation of a Multi-Epitope Gliadin Peptide Construct as a Novel Drug Substance Candidate for Epicutaneous Immunotherapy (EPIT) in Celiac Disease - Tobias L Freitag
• Safety and Efficacy of TAK-101: Results from a Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Phase 2 Trial in Patients with Celiac Disease on a Gluten-Free Diet - Jocelyn A Silvester
• Clinical, histologic and safety outcomes of ZED1227 treatment in symptomatic celiac disease patients: results from the phase 2b CEC-004/CEL randomized clinical trial - Detlef Schuppan
• Optimising Coeliac Disease Trials Through Participant-Centred Design: Motivators, Preferences and Gluten Challenge Acceptability - Amalia Marino
• Role of gut epithelial-cell derived transglutaminase 2 in the formation of celiac disease autoantibodies - Fleur du Pre

Invite only.

Invited Speakers:

• Professor Ludvig Sollid - 'Transglutaminase and B Cells in Celiac Disease Pathogenesis'
• Professor Bana Jabri, Bana Jabri Bendelac - 'Mechanisms of Tissue Damage'
• Professor Nicole La Gruta, Monash University - 'Single Cell Omics and Gluten-Specific T cells in Celiac Disease'

Abstract Speakers:

• A predisposing effect of HLA class II genes in celiac disease by skewing the naive CD4⁺ T-cell receptor repertoire - Ida Lindeman
• A dual role for IFNγ in epithelial injury and crypt hyperplasia in celiac disease - Joram Mooiweer
• High resolution spatial transcriptomics reveals changes in barrier function and stromal-epithelial-immune interactions in celiac disease - Karolina Künnapuu

Invited Speakers:

• Professor Joseph Murray, Mayo Clinic - 'A Clinical Approach to NRCD'
• Dr Fabiana Zingone, University of Padua - 'Revising Definitions of NRCD and RCD'
• Professor Gerd Bouma, Amsterdam University Medical Center - 'Emerging Therapeutics for RCD'

Abstract Speakers:

• Beyond the binary: shared clonal and molecular drivers link RCD1 and RCD2 in refractory coeliac disease - Anaïs Levescot
•  Intestinal Stem Cell Niche Dynamics in Celiac Disease: Implications of Gluten-Free-Diet Response. - Lalita Dr Mehra
• Functional screening of candidate antigens that may be driving the expansion of CD8⁺ T-cell clones with lymphoma driver mutations in type I refractory celiac disease  - Jennifer M Chen

Invited Speakers:

• Ms Marilyn Geller, Celiac Disease Foundation - 'Engaging the Celiac Patient in Research and Clinical Trials'
• Dr Debra Silberg, Beyond Celiac - 'Patient Burden of Celiac Disease'
• TBC

Followed by Panel Discussion.

Invited Speakers:

• Professor Fernando Chirdo, IIFP (UNLP-CONICET) - 'Celiac Disease in Latin America'
• Professor Govind Makharia, All India Institute of Medical Sciences - 'Celiac Disease in the Asia Pacific'
• Professor Chris Mulder, Amsterdam UMC Netherlands - 'Celiac Disease in Africa'
• Dr Mohamed Shiha, University of Sheffield - 'Celiac Disease in the Middle East'

Followed by Panel Discussion.

Invited Speakers:

• Associate Professor Jernej Dolinsek, University Medical Center Maribor - 'Challenges in Pediatric Celiac Diagnosis'
• Professor Luca Elli, University of Milano - 'Endoscopic Tools, VCE, Artificial Intelligence'
• Dr Robert (Bob) Anderson, Novoviah Pharmaceuticals - 'T cell Diagnostics - Celiac Disease and Beyond'

Followed by Panel Discussion.

Abstract Speakers:

• Accuracy of New European Adult Guidelines for Serology-Based Diagnosis of Celiac Disease in a United States Population - Claire Jansson-Knodell
• Beyond Anti-tTG: Multiplex Neo-Epitope Serology Improves Pediatric Celiac Disease Diagnosis and Supports Biopsy Avoidance - Patricia Wusterhausen
• Predicting celiac disease enteropathy using novel non-invasive protein biomarkers - Diksha Dr. Jha